Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureAnna Gamell, Eneritz Velasco-Arnaiz, David Aguilera-Alonso, Maria Goretti López-Ramos
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
New frontier on antimicrobial therapy: long-acting lipoglycopeptides.
10.3390/pathogens13030189 · 2024
Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement.
10.1093/jac/dku401 · 2015
Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review.
10.1016/s1473-3099(17)30345-6 · 2018
Bridging the gap: a systematic review with expert opinion on the use of dalbavancin for in-label and off-label indications in pediatric patients.
10.3390/antibiotics14020121 · 2025
Adjustment and homesickness in hospitalised children: a systematic review.
10.1016/j.cpr.2024.102431 · 2024
Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review.
10.1007/s40265-015-0505-8 · 2015
New perspectives on antimicrobial agents: long-acting lipoglycopeptides.
10.1128/aac.02614-20 · 2022
The safety and efficacy of dalbavancin and active comparator in pediatric patients with acute bacterial skin and skin structure infections.
10.1097/inf.0000000000003798 · 2023
Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age.
10.1097/inf.0000000000000646 · 2015
Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age.
10.1097/inf.0000000000001538 · 2017
Population pharmacokinetic and pharmacokinetic/pharmacodynamic target attainment analyses for dalbavancin in pediatric patients.
10.1097/inf.0000000000003764 · 2023
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
10.1016/j.jgar.2017.06.003 · 2017
Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE).
10.1007/s10096-016-2845-z · 2017
#13 Dalbavancin activity against bacterial isolates from pediatric patients: results from the international dalbavancin evaluation of activity (IDEA) program for the United States and Europe (2019-2021).
10.1093/jpids/piac041.012 · 2022
Real-world use of dalbavancin for treatment of soft tissue and bone infection in children: safe, effective and hospital-time sparing.
2024
Case series: use of dalbavancin for invasive gram-positive infection in children.
2026
Off-label use of dalbavancin in children: a case series.
10.1093/jac/dkae212 · 2024
Case series: off-label use of dalbavancin in pediatric gram-positive infections.
10.1097/inf.0000000000004883 · 2025
TDM-guided dalbavancin treatment for complex staphylococcus aureus osteoarticular infections in children.
10.3390/antibiotics15020162 · 2026
Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel.
10.1016/j.ijantimicag.2023.106960 · 2023
Dalbavancin in clinical practice in Spain: a 2 year retrospective study.
10.1093/jacamr/dlac120 · 2022
Dalbavancin pharmacokinetics in an 18-month-old child undergoing extracorporeal membrane oxygenation.
10.1097/ftd.0000000000001325 · 2025
Oritavancin: mechanism of action.
10.1093/cid/cir920 · 2012
Oritavancin as sequential therapy for Gram-positive bloodstream infections.
10.1186/s12879-023-08725-8 · 2024
Multidose dalbavancin population pharmacokinetic analysis for prolonged target attainment in patients requiring long-term treatment.
10.3390/antibiotics14020190 · 2025
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.
10.1128/aac.01830-24 · 2025
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection.
10.1093/jac/dkag039 · 2026
Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review.
10.1093/jac/dkag117 · 2026
Oritavancin multiple dosing for complex infections: a pharmacokinetic/pharmacodynamic simulation study.
10.3390/pharmaceutics18050628 · 2026
Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial.
10.1001/jama.2025.12543 · 2025
No additional external references are available.